49
total announcements
GLAND.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹50,366 Cr
P/E (TTM)
44.6
P/E (Forward)
31.7
EPS (TTM)
₹68.47
52W Low
₹1,573.60
52W High
₹3,171.00
Dividend Yield
0.65%
Beta
0.58
Price / Book
4.9
Debt / Equity
2.7
Revenue (TTM)
₹6,725 Cr
Gross Margin
59.16%
Operating Margin
21.00%
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the securities received for dematerialisation during the quarter ended September 30, 2026.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the dispatch of Notice of Postal Ballot and e-voting information, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange regarding Notice of Postal Ballot to seek approval of Members, through Postal Ballot, by voting through electronic means (‘remote e-voting”) for the appointment of Mr. Xingli Wang as a Non-Executive & Non-Independent Director of the company.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc. The Board of Directors has also approved the resignation of Mr. Wenjie Zhang and the appointment of Mr. Xingli Wang as an Additional Director.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026. The Board has approved investment of USD 21 million by the Company in Gland Pharma USA Inc. and appointment of Mr. Xingli Wang as an Additional Director.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about a newspaper publication titled 'Notice for attention of members of Gland Pharma Limited' to request shareholders to register/update their email address for receiving statutory communications in electronic form.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the acquisition of 100% of the equity share capital of Gland Pharma USA Inc., a wholly-owned step down subsidiary of the Company, from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 13, 2026, where the Board of Directors has approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the allotment of 44,193 Equity Shares on exercise of Employee Stock Options. The ESOP Compensation Committee has approved the formal closure and winding up of the Gland Pharma Limited Employee Stock Option Scheme, 2019 with immediate effect. The issued, subscribed and paid-up share capital of the Company stands increased to Rs. 165,010,854/- comprising 165,010,854 Equity shares of face value Re.1/- each.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the grant of stock options under the Gland Pharma Employee Stock Option Scheme 2025 to 124 employees of the Company.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about Board comments on fines levied by the Exchanges for non-compliance with the requirements pertaining to the appointment of a Non-Executive Director aged over 75 years.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the schedule of Analyst/Institutional Investor Meetings to be held on September 16, 17, and 25, 2026.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the schedule of Analyst/Institutional Investor Meetings, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the schedule of Analyst/Institutional Investor Meetings to be held on September 09, 2026, with Kotak Mutual Fund for a one-on-one meeting.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about General Updates regarding the United States Food and Drug Administration (USFDA) inspection at its Visakhapatnam facility between August 2022 and September 2022, which was conducted with zero observations.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange about the schedule of meet with investors and analysts.
Gland Pharma Limited
Gland Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 25, 2026, and informed the Exchange regarding voting results.
Gland Pharma Limited
Gland Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 25, 2026, where the company has taken all possible steps to ensure that the shareholders are provided with an opportunity to participate at the Annual General Meeting and also to vote.